Zobrazeno 1 - 10
of 283
pro vyhledávání: '"Michael R McClung"'
Autor:
Michael R. McClung, Michael A. Bolognese, Jacques P. Brown, Jean‐Yves Reginster, Bente L. Langdahl, Yifei Shi, Jen Timoshanko, Cesar Libanati, Arkadi Chines, Mary K. Oates
Publikováno v:
JBMR Plus, Vol 5, Iss 7, Pp n/a-n/a (2021)
ABSTRACT Romosozumab, a monoclonal anti‐sclerostin antibody that has the dual effect of increasing bone formation and decreasing bone resorption, reduces fracture risk within 12 months. In a post hoc, exploratory analysis, we evaluated the effects
Externí odkaz:
https://doaj.org/article/e0b2fb4a5a8b4695a0b58acc5354c9e5
Autor:
Chih-Hsing Wu, Wei-Chieh Hung, Ing-Lin Chang, Tsung-Ting Tsai, Yin-Fan Chang, Eugene V. McCloskey, Nelson B. Watts, Michael R. McClung, Chun-Feng Huang, Chung-Hwan Chen, Kun-Ling Wu, Keh-Sung Tsai, Ding-Cheng Chan, Jung-Fu Chen, Shih-Te Tu, Jawl-Shan Hwang, Weibo Xia, Toshio Matsumoto, Yoon-Sok Chung, Cyrus Cooper, John A. Kanis, Rong-Sen Yang, Wing P. Chan
Publikováno v:
Bone Reports, Vol 13, Iss , Pp 100729- (2020)
Objectives: Emerging evidence has indicated a role for pharmacologic agents in the primary prevention of osteoporotic fracture, but have not yet been systematically reviewed for meta-analysis. We conducted a meta-analysis to evaluate the efficacy of
Externí odkaz:
https://doaj.org/article/81a5d8098a084b9db4e9456be94af766
Autor:
E. Michael Lewiecki, John P. Bilezikian, Neil Binkley, Mary L. Bouxsein, Susan V. Bukata, David W. Dempster, Matthew T. Drake, Michael R. McClung, Paul D. Miller, Elisabeth Rosenthal, Laura L. Tosi
Publikováno v:
Journal of Clinical Densitometry. 25:649-667
The 22supnd/supAnnual Santa Fe Bone Symposium (SFBS) was a hybrid meeting held August 5-6, 2022, with in-person and virtual attendees. Altogether, over 400 individuals registered, a majority of whom attended in-person, representing many states in the
Autor:
Michael R. McClung
Publikováno v:
Osteoporosis and Sarcopenia, Vol 4, Iss 1, Pp 11-15 (2018)
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal qualit
Externí odkaz:
https://doaj.org/article/54fbb6e0351949f0ace861e8142f8969
Autor:
Michael R. McClung
Publikováno v:
Osteoporosis and Sarcopenia, Vol 3, Iss 1, Pp 8-17 (2017)
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand pati
Externí odkaz:
https://doaj.org/article/6f4690fd403f4736944ec5ff87dadcf3
Autor:
Michael R, McClung, Risa, Kagan, Shelli, Graham, Brian, Bernick, Sebastian, Mirkin, Ginger, Constantine
Publikováno v:
Menopause. 29:304-308
To evaluate bone turnover markers (BTM) in the REPLENISH trial (NCT01942668).REPLENISH evaluated oral estradiol/progesterone (E2/P4) for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal women with a uterus. Eligible wome
Autor:
Michael R. McClung
Publikováno v:
Endocrinology and Metabolism, Vol 30, Iss 4, Pp 429-435 (2015)
Although several effective therapies are available for the treatment of osteoporosis in postmenopausal women and older men, there remains a need for the development of even more effective and acceptable drugs. Several new drugs that are in late-stage
Externí odkaz:
https://doaj.org/article/a738d27b4af847b1b73a856f0902d650
Autor:
Michael R, McClung
Publikováno v:
Menopause (New York, N.Y.). 29(11)
Autor:
Michael R. McClung, Micol S. Rothman, E. Michael Lewiecki, David A. Hanley, Steven T. Harris, Paul D. Miller, David L. Kendler
Publikováno v:
Postgraduate medicine. 134(6)
Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification
Autor:
B. Stollenwerk, K. Adachi, Shravanthi R. Gandra, Michael R. McClung, Kiyoshi Tanaka, H. Hagino, S. Silverman, M. Charokopou, B. Johnson
Publikováno v:
Osteoporosis International. 32:2011-2021
Summary This study assessed the cost effectiveness of romosozumab versus teriparatide, both sequenced to alendronate, for the treatment of severe postmenopausal osteoporosis in Japan, using bone mineral density (BMD) efficacy data. Results show that